Multiple inheritance patterns have been reported for Hutchinson-Gilford progeria syndrome, including autosomal dominant and autosomal recessive forms. The condition is associated with the LMNA gene, located on chromosome 1. The ClinGen validity classification for this gene-disease relationship is not specified in this packet. No ClinVar variant data is included in this packet, so the spectrum of reported pathogenic variants cannot be summarized here. No certified molecular mechanism information is provided in this packet.

This packet does not include certified diagnostic methods or specific diagnostic criteria for Hutchinson-Gilford progeria syndrome. The LMNA gene on chromosome 1 is packet-certified as associated with this condition, and its role may be relevant to diagnostic evaluation, though no testing hierarchy or confirmation requirement is established by this packet. Newborn screening for this condition is not included in any certified panel according to this packet. Diagnostic approaches are therefore not described beyond the certified gene association.

Foundational therapy information is not certified in this packet. Regarding FDA-approved treatments, lonafarnib (brand name ZOKINVY) holds active FDA approval, granted in 2020, indicated to reduce the risk of mortality in Hutchinson-Gilford progeria syndrome in patients 12 months of age and older with a body surface area of 0.39 m² and above. Two additional substances, salicylsalicylic acid and progerinin, hold orphan drug designations only; orphan designation is a separate status from FDA approval and does not indicate that these substances are approved or currently available as treatments.

The condition is described in this packet as rare and fatal. Beyond this characterization, certified natural history or detailed prognosis data are not provided in this packet. The definition notes the condition begins in childhood. No additional course, survival, life expectancy, or outcome information is certified in this packet, and no further prognosis claims are made here.

Certified active trial records are present for Hutchinson-Gilford progeria syndrome. One certified Phase 2 trial (NCT06775041), sponsored by PRG Science & Technology Co., Ltd., is studying the optimal dose, safety, tolerability, and pharmacokinetics of progerinin in people with HGPS; its status is active but not recruiting. A separate certified Phase 1/2 trial (NCT02579044), sponsored by Boston Children's Hospital, is evaluating everolimus in combination with lonafarnib in progeria, with enrollment by invitation. Active clinical trials for this condition are listed on ClinicalTrials.gov.